サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468146

腎臓がん治療・診断の市場レポート：成分別、がんタイプ別、用途別、地域別、2024～2032年

Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
腎臓がん治療・診断の市場レポート：成分別、がんタイプ別、用途別、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がん治療・診断市場規模は2023年に51億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに88億米ドルに達し、2024～2032年の間に6.22%の成長率（CAGR）を示すと予測しています。腎臓がんの罹患率の上昇、高齢者人口の増加、いくつかの政府による有利なイニシアチブは、市場を牽引する主要要因のいくつかです。

腎臓がんは、腎臓組織で異常な細胞増殖が起こり、腫瘍化する慢性疾患です。その症状には、血尿、食欲不振、脇腹痛、疲労感、発熱、体重減少、骨痛、高血圧、貧血などがあります。腎臓がんは、血液試験や尿試験、生検、バイオマーカー試験、コンピューター断層撮影（CT）スキャン、X線試験、磁気共鳴画像法（MRI）、膀胱鏡試験、腎尿管鏡試験など、さまざまな手法で診断されます。治療法としては、薬剤療法、化学療法、放射線療法、腎摘除術、凍結融解壊死療法、ラジオ波焼灼療法、分子標的治療などがあります。腎臓がんの治療や診断薬はがん細胞の除去を助け、腫瘍を破壊し再発を防ぎ、医師が治療計画を立てるのを助ける。また、腎機能の改善、将来の合併症の軽減、がんの転移抑制、患者の快適性の向上にも役立ちます。

腎臓がん治療と診断薬の市場動向：

喫煙習慣、肥満、遺伝的条件、化学物質への曝露の増加による腎臓がんの発生率の上昇は、市場成長を促進する主要要因の1つです。腎がん治療と診断薬は、腎細胞がん（RCC）、良性腎腫瘍、ウィルムス腫瘍、移行細胞がん、腎肉腫、髄様がん、多眼嚢胞性RCC、粘液性尿細管がんと紡錘細胞がんの分析と治療に広く使用されています。さらに、腎細胞がんやその他の腎臓がんに罹患しやすい高齢者人口の増加が、腫瘍の管理、生存期間の延長、腎臓の非がん部分の温存のための治療や診断薬に対する需要を促進しています。さらに、明細胞RCCの早期発見と患者の予後予測の重要な指標であるバキュロウイルスIAPリピート含有5（BIRC5）などのバイオマーカーを検出できる診断ツールの最近の発展は、市場の成長にプラスの影響を与えています。これとは別に、腎臓とその腫瘍の術前モデルを作成するための3次元（3D）プリンティングの採用が、ひいては治療計画や患者への適切なカウンセリングの提供において医師を支援し、手術ミスを減らし、効率を高め、腎臓機能の大部分を維持することが、市場成長に好影響を与えています。さらに、がんに関する認識を広めるために政府がさまざまな取り組みを実施していることも、市場に明るい展望をもたらしています。医療産業の著しい成長、潜在的な治療選択肢を特定するための研究開発（R&D）活動への投資の増加、ロボット手術、遠隔医療、人工知能（AI）などの先進技術の普及などのその他の要因も、市場の成長をさらに促進すると予測されます。

本レポートで扱う主要質問

  • 世界の腎臓がん治療・診断市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界の腎臓がん治療・診断市場における市場の促進要因、抑制要因、機会は何か？
  • 主要な地域市場は？
  • 最も魅力的な腎臓がん治療・診断市場はどの国か？
  • 成分別の市場内訳は？
  • がんタイプ別の市場内訳は？
  • 用途別の市場内訳は？
  • 世界の腎臓がん治療・診断市場の競合構造は？
  • 世界の腎臓がん治療・診断市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 腎臓がん治療・診断の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：成分別

  • 医薬品
    • 市場動向
    • 主要セグメント
      • 薬剤：治療クラス別
        • 標的療法
        • 免疫療法
        • その他
      • 薬剤：薬剤クラス別
        • 血管新生阻害薬
        • mTOR阻害薬
        • モノクローナル抗体
        • サイトカイン免疫療法（II-2）
    • 市場予測
  • 診断
    • 市場動向
    • 主要セグメント
      • 画像試験
      • 生検
      • 血液試験
      • その他
    • 市場予測

第7章 市場内訳：がんタイプ別

  • 透明細胞RCC
  • 乳頭状RCC
  • 発色性RCC
  • 移行細胞がん
  • その他

第8章 市場内訳：用途別

  • 病院
  • 医薬品ラボ
  • ゲノミクス研究所
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bristol-Myers Squibb Company
    • Exelixis Inc.
    • Genentech Inc.（Roche Holding AG）
    • Novartis AG
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2023
  • Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2023
  • Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
  • Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million US$), 2024-2032
  • Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
  • Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players
目次
Product Code: SR112024A7528

The global kidney cancer therapeutics and diagnostics market size reached US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.8 Billion by 2032, exhibiting a growth rate (CAGR) of 6.22% during 2024-2032. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.

Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.

Kidney Cancer Therapeutics and Diagnostics Market Trends:

The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global kidney cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on component, cancer types, and application.

Component Insights:

Drugs

Drugs by Therapeutic Class

Targeted Therapy

Immunotherapy

Others

Drugs by Pharmacologic Class

Angiogenesis Inhibitors

mTOR Inhibitors

Monoclonal Antibodies

Cytokine Immunotherapy (II-2)

Diagnostics

Imaging Test

Biopsy

Blood Test

Others

The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.

Cancer Types Insights:

Clear Cell RCC

Papillary RCC

Chromophobe RCC

Transitional Cell Carcinoma

Others

A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the cancer types has been provided in the report. This includes clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. According to the report, clear cell RCC accounted for the largest market share.

Application Insights:

Hospitals

Pharmaceutical Labs

Genomic Laboratories

Others

A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the application has been provided in the report. This includes hospitals, pharmaceutical labs, genomic laboratories, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global kidney cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global kidney cancer therapeutics and diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive kidney cancer therapeutics and diagnostics markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the cancer types?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global kidney cancer therapeutics and diagnostics market?
  • Who are the key players/companies in the global kidney cancer therapeutics and diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Kidney Cancer Therapeutics and Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Drugs by Therapeutic Class
        • 6.1.2.1.1 Targeted Therapy
        • 6.1.2.1.2 Immunotherapy
        • 6.1.2.1.3 Others
      • 6.1.2.2 Drugs by Pharmacologic Class
        • 6.1.2.2.1 Angiogenesis Inhibitors
        • 6.1.2.2.2 mTOR Inhibitors
        • 6.1.2.2.3 Monoclonal Antibodies
        • 6.1.2.2.4 Cytokine Immunotherapy (II-2)
    • 6.1.3 Market Forecast
  • 6.2 Diagnostics
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Imaging Test
      • 6.2.2.2 Biopsy
      • 6.2.2.3 Blood Test
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Cancer Types

  • 7.1 Clear Cell RCC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Papillary RCC
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chromophobe RCC
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Transitional Cell Carcinoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmaceutical Labs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Genomics Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Bristol-Myers Squibb Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Exelixis Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Genentech Inc. (Roche Holding AG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Pfizer Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.